1. Home
  2. GKOS vs DVAX Comparison

GKOS vs DVAX Comparison

Compare GKOS & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GKOS
  • DVAX
  • Stock Information
  • Founded
  • GKOS 1998
  • DVAX 1996
  • Country
  • GKOS United States
  • DVAX United States
  • Employees
  • GKOS N/A
  • DVAX N/A
  • Industry
  • GKOS Medical/Dental Instruments
  • DVAX Biotechnology: Pharmaceutical Preparations
  • Sector
  • GKOS Health Care
  • DVAX Health Care
  • Exchange
  • GKOS Nasdaq
  • DVAX Nasdaq
  • Market Cap
  • GKOS 5.4B
  • DVAX 1.3B
  • IPO Year
  • GKOS 2015
  • DVAX 2004
  • Fundamental
  • Price
  • GKOS $85.82
  • DVAX $9.75
  • Analyst Decision
  • GKOS Strong Buy
  • DVAX Buy
  • Analyst Count
  • GKOS 12
  • DVAX 4
  • Target Price
  • GKOS $128.58
  • DVAX $26.50
  • AVG Volume (30 Days)
  • GKOS 707.0K
  • DVAX 2.0M
  • Earning Date
  • GKOS 11-03-2025
  • DVAX 11-06-2025
  • Dividend Yield
  • GKOS N/A
  • DVAX N/A
  • EPS Growth
  • GKOS N/A
  • DVAX N/A
  • EPS
  • GKOS N/A
  • DVAX N/A
  • Revenue
  • GKOS $432,953,000.00
  • DVAX $316,268,000.00
  • Revenue This Year
  • GKOS $28.84
  • DVAX $23.23
  • Revenue Next Year
  • GKOS $25.72
  • DVAX $16.57
  • P/E Ratio
  • GKOS N/A
  • DVAX N/A
  • Revenue Growth
  • GKOS 26.70
  • DVAX 26.66
  • 52 Week Low
  • GKOS $77.10
  • DVAX $9.20
  • 52 Week High
  • GKOS $163.71
  • DVAX $14.63
  • Technical
  • Relative Strength Index (RSI)
  • GKOS 43.60
  • DVAX 43.66
  • Support Level
  • GKOS $80.53
  • DVAX $9.20
  • Resistance Level
  • GKOS $95.32
  • DVAX $9.94
  • Average True Range (ATR)
  • GKOS 3.04
  • DVAX 0.31
  • MACD
  • GKOS -0.85
  • DVAX -0.01
  • Stochastic Oscillator
  • GKOS 32.13
  • DVAX 50.00

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Share on Social Networks: